Clinical characteristics of HIV patients with lymphoma
. | Study population . | HIV score 0 . | HIV score 1 . | HIV score 2-3 . |
|---|---|---|---|---|
| Sex, no. male (%) | 414 (85) | 188 (86) | 148 (84) | 78 (86) |
| Median age, y (range) | 37 (18-67) | 37 (18-67) | 39 (23-67) | 36 (24-61) |
| Lymphoma characteristics, no. (%) | ||||
| Stage III—IV | 303 (62) | 143 (66) | 103 (58) | 57 (63) |
| B symptoms | 252 (52) | 89 (41) | 102 (58) | 61 (67) |
| Tumor size at least 10 cm | 76 (16) | 36 (17) | 28 (16) | 12 (13) |
| Performance status at least 2 | 82 (17) | 1 (0) | 31 (18) | 50 (55) |
| At least 2 extranodal sites | 167 (34) | 75 (34) | 64 (36) | 28 (31) |
| Bone marrow involvement | 76 (16) | 36 (17) | 26 (15) | 14 (16) |
| CNS involvement | 37 (8) | 25 (11) | 9 (5) | 3 (3) |
| LDH level above normal | 268 (55) | 113 (52) | 104 (59) | 51 (57) |
| Albumin level less than 35 g/L | 182 (38) | 70 (32) | 63 (36) | 49 (54) |
| aaIPI score at least 2 | 227 (47) | 92 (47) | 84 (47) | 51 (56) |
| HIV characteristics | ||||
| Sexual transmission, no. (%) | 212 (52) | 109 (50) | 69 (39) | 34 (38) |
| Drug use, no. (%) | 111 (23) | 44 (20) | 44 (25) | 23 (26) |
| Time between HIV and lymphoma, mo (range) | 52 (0-170) | 40 (0-170) | 58 (0-162) | 72 (0-157) |
| AIDS prior to NHL, no. (%) | 99 (20) | 0 (0) | 30 (17) | 69 (77) |
| CD4+ cells | ||||
| Median count per mm3 (range) | 129 (1-1584) | 239 (100-1584) | 72 (2-652) | 21 (1-924) |
| Count less than 100/mm3, no. (%) | 189 (39) | 6 (3) | 106 (60) | 77 (86) |
| Infection before NHL, no. (%) | 103 (21) | 9 (4) | 34 (19) | 60 (66) |
. | Study population . | HIV score 0 . | HIV score 1 . | HIV score 2-3 . |
|---|---|---|---|---|
| Sex, no. male (%) | 414 (85) | 188 (86) | 148 (84) | 78 (86) |
| Median age, y (range) | 37 (18-67) | 37 (18-67) | 39 (23-67) | 36 (24-61) |
| Lymphoma characteristics, no. (%) | ||||
| Stage III—IV | 303 (62) | 143 (66) | 103 (58) | 57 (63) |
| B symptoms | 252 (52) | 89 (41) | 102 (58) | 61 (67) |
| Tumor size at least 10 cm | 76 (16) | 36 (17) | 28 (16) | 12 (13) |
| Performance status at least 2 | 82 (17) | 1 (0) | 31 (18) | 50 (55) |
| At least 2 extranodal sites | 167 (34) | 75 (34) | 64 (36) | 28 (31) |
| Bone marrow involvement | 76 (16) | 36 (17) | 26 (15) | 14 (16) |
| CNS involvement | 37 (8) | 25 (11) | 9 (5) | 3 (3) |
| LDH level above normal | 268 (55) | 113 (52) | 104 (59) | 51 (57) |
| Albumin level less than 35 g/L | 182 (38) | 70 (32) | 63 (36) | 49 (54) |
| aaIPI score at least 2 | 227 (47) | 92 (47) | 84 (47) | 51 (56) |
| HIV characteristics | ||||
| Sexual transmission, no. (%) | 212 (52) | 109 (50) | 69 (39) | 34 (38) |
| Drug use, no. (%) | 111 (23) | 44 (20) | 44 (25) | 23 (26) |
| Time between HIV and lymphoma, mo (range) | 52 (0-170) | 40 (0-170) | 58 (0-162) | 72 (0-157) |
| AIDS prior to NHL, no. (%) | 99 (20) | 0 (0) | 30 (17) | 69 (77) |
| CD4+ cells | ||||
| Median count per mm3 (range) | 129 (1-1584) | 239 (100-1584) | 72 (2-652) | 21 (1-924) |
| Count less than 100/mm3, no. (%) | 189 (39) | 6 (3) | 106 (60) | 77 (86) |
| Infection before NHL, no. (%) | 103 (21) | 9 (4) | 34 (19) | 60 (66) |
For the whole study population, n = 485. For those with an HIV score of 0, n = 218; of 1, n = 177; and of 2-3, n = 90.